Cancer Treatment Reviews
Volume 30, Issue 3 , Pages 269-280 , May 2004

Soft tissue sarcomas of childhood

  • William H Meyer

      Affiliations

    • Hematology/Oncology Section, Department of Pediatrics, University of Oklahoma Health Sciences Center, P.O. Box 26901, Oklahoma City, OK 73190, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-405-271-5311; fax: +1-405-271-3756
    • ,
  • Sheri L Spunt

      Affiliations

    • St. Jude Children's Research Hospital, Department of Hematology/Oncology, 332 N. Lauderdale Street, Memphis, TN 38105-2794, USA
    • Tel.: +1-901-495-3984; fax:+1-901-521-9005.

References 

  1. Ries LAG, Smith MA, Gurney JG, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995 [NIH Pub. No. 99-4649]. Bethesda, MD: National Cancer Institute, SEER Program; 1999
  2. Pratt CB, Pappo AS, Gieser P, et al.  Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study. J. Clin. Oncol. 1999;17:1219–1226
  3. Spunt SL, Poquette CA, Hurt YS, et al.  Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St. Jude Children's Research Hospital. J. Clin. Oncol. 1999;17:3697–3705
  4. Marcus KC, Grier HE, Shamberger RC, et al.  Childhood soft tissue sarcoma: a 20-years experience. J. Pediatr. 1997;131:603–607
  5. Maurer HM, Beltangady M, Gehan EA, et al.  The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988;61:209–220
  6. Maurer HM, Gehan EA, Beltangady M, et al.  The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993;71:1904–1922
  7. Crist W, Gehan EA, Ragab AH, et al.  The Third Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 1995;13:610–630
  8. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl. J. Med. 1999;341:342–352
  9. Crist WM, Anderson JR, Meza JL, et al.  Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol. 2001;19:3091–3102
  10. Baker KS, Anderson JR, Lobe TE, et al.  Children from ethnic minorities have benefited equally as other children from contemporary therapy for rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J. Clin. Oncol. 2002;20:4428–4433
  11. Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J. Clin. Oncol. 1995;13:2123–2139
  12. Koscielniak E, Harms D, Henze G, et al.  Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J. Clin. Oncol. 1999;17:3706–3719
  13. Neville HL, Andrassy RJ, Lobe TE, et al.  Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991–1997). J. Pediatr. Surg. 2000;35:317–321
  14. Wiener ES, Anderson JR, Ojimba JI, et al.  Controversies in the management of paratesticular rhabdomyosarcoma: Is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?. Semin. Pediatr. Surg. 2001;10:146–152
  15. Raney RB, Tefft M, Maurer HM, et al.  Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I. Cancer. 1988;62:1257–1266
  16. Yang P, Grufferman S, Khoury MJ, et al.  Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects. Genet. Epidemiol. 1995;12:467–474
  17. Smith AC, Squire JA, Thorner P, et al.  Association of alveolar rhabdomyosarcoma with the Beckwith–Wiedemann syndrome. Pediatr. Dev. Pathol. 2001;4:550–558
  18. Cohen PR, Kurzrock R. Miscellaneous genodermatoses: Beckwith–Wiedemann syndrome, Birt–Hogg–Dube syndrome, familial atypical multiple mole melanoma syndrome, hereditary tylosis, incontinentia pigmenti, and supernumerary nipples. Dermatol. Clin. 1995;13:211–229
  19. Malkin D, Li FP, Strong LC, et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233–1238
  20. Heyn R, Haeberlen V, Newton WA, et al.  Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. J. Clin. Oncol. 1993;11:262–270
  21. Bisogno G, Murgia A, Mammi I, Strafella MS, Carli M. Rhabdomyosarcoma in a patient with cardio-facio-cutaneous syndrome. J. Pediatr. Hematol. Oncol. 1999;21:424–427
  22. Gripp KW, Scott CIJ, Nicholson L, et al.  Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am. J. Med. Genet. 2002;108:80–87
  23. Ruymann FB, Maddux HR, Ragab A, et al.  Congenital anomalies associated with rhabdomyosarcoma: an autopsy study of 115 cases. A report from the Intergroup Rhabdomyosarcoma Study Committee (representing the Children's Cancer Study Group, the Pediatric Oncology Group, the United Kingdom Children's Cancer Study Group, and the Pediatric Intergroup Statistical Center). Med. Pediatr. Oncol. 1988;16:33–39
  24. Grufferman S, Schwartz AG, Ruymann FB, Maurer HM. Parents' use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control. 1993;4:217–224
  25. Horn RC, Enterline HT. Rhabdomyosarcoma: a clinicopathological study and classification of 39 cases. Cancer. 1958;11:181–199
  26. Parham DM, Webber B, Holt H, Williams WK, Maurer H. Immunohistochemical study of childhood rhabdomyosarcomas and related neoplasms. Results of an Intergroup Rhabdomyosarcoma study project. Cancer. 1991;67:3072–3080
  27. Cessna MH, Zhou H, Perkins SL, et al.  Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am. J. Surg. Pathol. 2001;25(9):1150–1157
  28. Qualman SJ, Coffin CM, Newton WA, et al.  Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr. Dev. Pathol. 1998;1:550–561
  29. Newton WAJ, Gehan EA, Webber BL, et al.  Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification – an Intergroup Rhabdomyosarcoma Study. Cancer. 1995;76:1073–1085
  30. Kodet R, Newton WAJ, Hamoudi AB, et al.  Childhood rhabdomyosarcoma with anaplastic (pleomorphic) features. A report of the Intergroup Rhabdomyosarcoma Study. Am. J. Surg. Pathol. 1993;17:443–453
  31. Scrable HJ, Witte DP, Lampkin BC, Cavenee WK. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature. 1987;329:645–647
  32. Loh WEJ, Scrable HJ, Livanos E, et al.  Human chromosome 11 contains two different growth suppressor genes for embryonal rhabdomyosarcoma. Proc. Natl. Acad. Sci. USA. 1992;89:1755–1759
  33. El-Badry OM, Minniti C, Kohn EC, et al.  Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ. 1990;1:325–331
  34. Bridge JA, Liu J, Weibolt V, et al.  Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study. Genes Chromosome Cancer. 2000;27:337–344
  35. Douglass EC, Shapiro DN, Valentine M, et al.  Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations. Med. Pediatr. Oncol. 1993;21:83–87
  36. Barr FG, Galili N, Holick J, et al.  Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat. Genet. 1993;3:113–117
  37. Sorensen PH, Lynch JC, Qualman SJ, et al.  PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol. 2002;20:2672–2679
  38. Barr FG, Chatten J, D'Cruz CM, et al.  Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. JAMA. 1995;273:553–557
  39. Biegel JA, Nycum LM, Valentine V, Barr FG, Shapiro DN. Detection of the t(2;13) (q35;q14) and PAX3-FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridization. Genes Chromosome Cancer. 1995;12:186–192
  40. Collins MH, Zhao H, Womer RB, Barr FG. Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions. Med. Pediatr. Oncol. 2001;37:83–89
  41. Raney RBJ, Tefft M, Lawrence WJ, et al.  Paratesticular sarcoma in childhood and adolescence. A report from the Intergroup Rhabdomyosarcoma Studies I and II, 1973–1983. Cancer. 1987;60:2337–2343
  42. Wiener ES, Anderson JR, Ojimba JI, et al.  Controversies in the management of paratesticular rhabdomyosarcoma: Is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?. Semin. Pediatr. Surg. 2001;10:146–152
  43. Lawrence WJ, Hays DM, Heyn R, et al.  Lymphatic metastases with childhood rhabdomyosarcoma. A report from the Intergroup Rhabdomyosarcoma Study. Cancer. 1987;60:910–915
  44. Andrassy RJ, Corpron CA, Hays D, et al.  Extremity sarcomas: an analysis of prognostic factors from the Intergroup Rhabdomyosarcoma Study III. J. Pediatr. Surg. 1996;31:191–196
  45. Paganelli G, De Cicco C, Chinol M. Sentinel node localization by lymphoscintigraphy: a reliable technique with widespread applications. Recent Results Cancer Res. 2000;157:121–129
  46. Lawrence WJ, Gehan EA, Hays DM, Beltangady M, Maurer HM. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J. Clin. Oncol. 1987;5:46–54
  47. Lawrence WJ, Anderson JR, Gehan EA, Maurer H. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group. Cancer. 1997;80:1165–1170
  48. Hays DM, Lawrence WJ, Wharam M, et al.  Primary reexcision for patients with `microscopic residual' tumor following initial excision of sarcomas of trunk and extremity sites. J. Pediatr. Surg. 1989;24:5–10
  49. Cecchetto G, Carli M, Sotti G, et al.  Importance of local treatment in pediatric soft tissue sarcomas with microscopic residual after primary surgery: results of the Italian Cooperative Study RMS-88. Med. Pediatr. Oncol. 2000;34:97–101
  50. Horowitz ME, Etcubanas E, Christensen ML, et al.  Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J. Clin. Oncol. 1988;6:308–314
  51. Breitfeld PP, Lyden E, Beverly RR, et al.  Ifosfamide and Etoposide are Superior to Vincristine and Melphalan for Pediatric Metastatic Rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. Am. J. Pediatr. Hematol. Oncol. 2001;23:225–233
  52. Pappo AS, Bowman LC, Furman WL, et al.  A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma. J. Pediatr. Hematol. Oncol. 1997;19:438–442
  53. Sandler E, Lyden E, Ruymann F, et al.  Efficacy of ifosfamide and doxorubicin given as a phase II “window” in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med. Pediatr. Oncol. 2001;37:442–448
  54. Crist WM, Raney RB, Ragab A, et al.  Intensive chemotherapy including cisplatin with or without etoposide for children with soft-tissue sarcomas. Med. Pediatr. Oncol. 1987;15:51–57
  55. Pappo AS, Etcubanas E, Santana VM, et al.  A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. Cancer. 1993;71:2119–2125
  56. Pappo AS, Lyden E, Breneman J, et al.  Up-front window trial of topotecan in previously untreated children and adolescents with metastatic Rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 2001;19:213–219
  57. Meyer WH, Breitfeld PP, Lyden ER, et al.  The drug pair, topotecan/cyclophosphamide, is active in previously untreated rhabdomyosarcoma (RMS): a report from the Intergroup Rhabdomyosarcoma Study Group (IRSG) [abstract]. Proc. Annu. Meet Am. Soc. Clin. Oncol. 2000;19:582a
  58. Pappo AS, Lyden E, Breitfeld PP, et al.  Irinotecan (CPT-11) is active against pediatric rhabdomyosarcoma(RMS): a phase II window trial from the Soft Tissue Sarcoma Committee (STS) of the Children's Oncology Group (COG) [abstract]. Proc. Annu. Meet Am. Soc. Clin. Oncol. 2002;21:
  59. Furman WL, Stewart CF, Poquette CA, et al.  Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J. Clin. Oncol. 1999;17:1815–1824
  60. Cosetti M, Wexler LH, Calleja E, et al.  Irinotecan for pediatric solid tumors: The Memorial Sloan Kettering experience. J. Pediatr. Hematol. Oncol. 2002;24:101–105
  61. Miser JS, Kinsella TJ, Triche TJ, et al.  Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J. Clin. Oncol. 1987;5:1191–1198
  62. Kung FH, Pratt CB, Vega RA, et al.  Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II Study. Cancer. 1993;71:1898–1903
  63. Houghton PJ, Cheshire PJ, Myers L, et al.  Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol. 1992;31:229–239
  64. Houghton PJ, Cheshire PJ, Hallman JC, et al.  Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10- (4- [1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9- dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res. 1993;53:2823–2829
  65. Vassal G, Pondarre C, Boland I, et al.  Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie. 1998;80:271–280
  66. Rodriguez-Galindo C, Radomski K, Stewart CF, et al.  Clinical use of topoisomerase I inhibitors in anticancer treatment. Med. Pediatr. Oncol. 2000;35:385–402
  67. Saylors RL, Stine KC, Sullivan J, et al.  Cyclophosphamide plus topotecan in children with recurrent or refractory Solid tumors: A Pediatric Oncology Group Phase II Study. J. Clin. Oncol. 2001;19:3463–3469
  68. Breneman JC, Lyden E, Pappo AS, et al.  Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma – a report from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 2003;21:78–84
  69. Meyer WH, Houghton PJ, Horowitz ME, et al.  Use of investigational drugs as initial therapy for childhood solid tumors. Hamatol. Bluttransfus. 1989;32:141–148
  70. Sutow WW, Berry DH, Haddy TB, et al.  Vincristine sulfate therapy in children with metastatic soft tissue sarcoma. Pediatrics. 1966;38:465–472
  71. Houghton JA, Cook RL, Lutz PJ, Houghton PJ. Childhood rhabdomyosarcoma xenografts: responses to DNA- interacting agents and agents used in current clinical therapy. Eur. J. Cancer Clin. Oncol. 1984;20:955–960
  72. Houghton JA, Meyer WH, Houghton PJ. Scheduling of vincristine: drug accumulation and response of xenografts of childhood rhabdomyosarcoma determined by frequency of administration. Cancer Treat Rep. 1987;71:717–721
  73. Thompson J, George EO, Poquette CA, et al.  Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin. Cancer Res. 1999;5:3617–3631
  74. Donaldson SS, Meza J, Breneman JC, et al.  Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma – a report from the IRSG. Int. J. Radiat. Oncol. Biol. Phys. 2001;51:718–728
  75. Raney RBJ, Tefft M, Newton WA, et al.  Improved prognosis with intensive treatment of children with cranial soft tissue sarcomas arising in nonorbital parameningeal sites. A report from the Intergroup Rhabdomyosarcoma Study. Cancer. 1987;59:147–155
  76. Raney RB, Meza J, Anderson JR, et al.  Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978–1997. Med. Pediatr. Oncol. 2002;38:22–32
  77. Andrassy RJ, Wiener ES, Raney RB, et al.  Progress in the surgical management of vaginal rhabdomyosarcoma: a 25-years review from the Intergroup Rhabdomyosarcoma Study Group. J. Pediatr. Surg. 1999;34:731–734
  78. Arndt CA, Donaldson SS, Anderson JR, et al.  What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?. Cancer. 2001;91:2454–2468
  79. Sklar CA, Constine LS. Chronic neuroendocrinological sequelae of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1995;31:1113–1121
  80. Oberfield SE, Sklar CA. Endocrine sequelae in survivors of childhood cancer. Adolesc. Med. 2002;13:161–169 viii
  81. Sklar CA. Growth following therapy for childhood cancer. Cancer Invest. 1995;13:511–516
  82. Spunt SL, Meza JL, Anderson JR, et al.  Second Malignant Neoplasms (SMN) in children treated for rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies (IRS) I-IV [abstract]. Proc. Annu. Meet Am. Soc. Clin. Oncol. 2001;20:2173
  83. Pappo AS, Anderson JR, Crist WM, et al.  Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J. Clin. Oncol. 1999;17:3487–3493
  84. Brown JM. The hypoxic cell: a target for selective cancer therapy – eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999;59:5863–5870
  85. Siim BG, Menke DR, Dorie MJ, Brown JM. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res. 1997;57:2922–2928
  86. Dagher R, Long LM, Read EJ, et al.  Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med. Pediatr. Oncol. 2002;38:158–164
  87. Miller VA, Johnson D, Heelan RT, et al.  A pilot trial demonstrates the safety of ZD1839 (`Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC) [abstract]. Proc. Annu. Meet Am. Soc. Clin. Oncol. 2001;20:
  88. Houghton PJ, Harwood FC, Sharif M. Epidermal growth factor activation of ERK 1/2 in pediatric cancer cell lines and sensitivity to the selective EGFR-tyrosine kinase inhibitor ZD1839 (Iressa) [abstract]. Proc. Am. Assoc. Cancer Res. 2000;41:
  89. Petak I, Douglas L, Tillman DM, Vernes R, Houghton JA. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin. Cancer Res. 2000;6:4119–4127
  90. Dilling MB, Dias P, Shapiro DN, et al.  Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res. 1994;54:903–907
  91. Hosoi H, Dilling MB, Shikata T, et al.  Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 1999;59:886–894
  92. Lack EE. Leiomyosarcomas in childhood: a clinical and pathologic study of 10 cases. Pediatr. Pathol. 1986;6:181–197
  93. Ferrari A, Casanova M, Spreafico F, et al.  Childhood liposarcoma: a single-institutional 20-years experience. Pediatr. Hematol. Oncol. 1999;16:415–421
  94. La Quaglia MP, Spiro SA, Ghavimi F, et al.  Liposarcoma in patients younger than or equal to 22 years of age. Cancer. 1993;72:3114–3119
  95. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18:184–187
  96. Rubin BP, Chen CJ, Morgan TW, et al.  Congenital mesoblastic nephroma t (12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol. 1998;153:1451–1458
  97. Knezevich SR, Garnett MJ, Pysher TJ, et al.  ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 1998;58:5046–5048
  98. Soule EH, Pritchard DJ. Fibrosarcoma in infants and children: a review of 110 cases. Cancer. 1977;40:1711–1721
  99. Coffin CM, Dehner LP. Soft tissue tumors in first year of life: a report of 190 cases. Pediatr Pathol. 1990;10:509–526
  100. McCarville MB, Kaste SC, Pappo AS. Soft-tissue malignancies in infancy. AJR Am J Roentgenol. 1999;173:973–977
  101. Rodriguez-Galindo C, Ramsey K, Jenkins JJ, et al.  Hemangiopericytoma in children and infants. Cancer. 2000;88:198–204
  102. Pappo AS, Rao BN, Jenkins JJ, et al.  Metastatic nonrhabdomyosarcomatous soft-tissue sarcomas in children and adolescents: the St. Jude Children's Research Hospital experience. Med Pediatr Oncol. 1999;33:76–82
  103. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993;217:72–77
  104. Jager PL, Hoekstra HJ, Leeuw J, et al.  Routine bone scintigraphy in primary staging of soft tissue sarcoma; Is it worthwhile?. Cancer. 2000;89:1726–1731
  105. Espat NJ, Bilsky M, Lewis JJ, Leung D, Brennan MF. Soft tissue sarcoma brain metastases. Prevalence in a cohort of 3829 patients. Cancer. 2002;94:2706–2711
  106. Carnevale A, Lieberman E, Cardenas R. Li–Fraumeni syndrome in pediatric patients with soft tissue sarcoma or osteosarcoma. Arch Med Res. 1997;28:383–386
  107. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist. 2000;5:477–485
  108. Green DM, Hyland A, Barcos MP, et al.  Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J. Clin. Oncol. 2000;18:1492–1499
  109. Dunst J, Ahrens S, Paulussen M, et al.  Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. Int J Radiat Oncol Biol Phys. 1998;42:379–384
  110. Kuttesch JF, Wexler RB, et al.  Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J. Clin. Oncol. 1996;14:2818–2825
  111. Eng C, Li FP, Abramson DH, et al.  Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85:1121–1128
  112. McClain KL, Leach CT, Jenson HB, et al.  Association of Epstein–Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med. 1995;332:12–18
  113. Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene. 2001;20:5755–5762
  114. Ladanyi M, Antonescu CR, Leung DH, et al.  Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135–140
  115. Parham DM, Webber BL, Jenkins JJ, Cantor AB, Maurer HM. Nonrhabdomyosarcomatous soft tissue sarcomas of childhood: formulation of a simplified system for grading. Mod Pathol. 1995;8:705–710
  116. Spunt SL, Hill DA, Motosue AM, et al.  Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. J. Clin. Oncol. 2002;20:3225–3235
  117. Jones DN, McCowage GB, Sostman HD, et al.  Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med. 1996;37:1438–1444
  118. Pratt CB, Maurer HM, Gieser P, et al.  Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: A Pediatric Oncology Group Study. Med Pediatr Oncol. 1998;30:201–209
  119. Pappo AS, Devidas M, Jenkins J, et al.  Vincristine (V), Ifosfamide (I), Doxorubicin (D), and G-CSF (G) for pediatric unresected metastatic non-rhabdomyosarcomatous soft tissue Sarcomas (NRSTS): A Pediatric Oncology Group (POG) Study [abstract]. Proc Annu Meet Am Soc Clin Oncol. 2001;20:378a
  120. Baldini EH, Goldberg J, Jenner C, et al.  Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J. Clin. Oncol. 1999;17:3252–3259
  121. Rydholm A, Gustafson P, Rooser B, et al.  Limb-sparing surgery without radiotherapy based on anatomic location of soft tissue sarcoma. J. Clin. Oncol. 1991;9:1757–1765
  122. Khanfir K, Alzieu L, Terrier P, et al.  Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities?. Eur J Cancer. 2003;39:1872–1880
  123. Frustaci S, Gherlinzoni F, De Paoli A, et al.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J. Clin. Oncol. 2001;19:1238–1247
  124. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350:1647–54
  125. Bramwell VH. Adjuvant chemotherapy for adult soft tissue sarcoma: Is there a standard of care?. J Clin Oncol. 2001;19:1235–1237
  126. Walter AW, Shearer PD, Pappo AS, et al.  A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Med Pediatr Oncol. 1998;30:210–216
  127. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am. 1995;9:765–785
  128. Patel SR, Vadhan-Raj S, Burgess MA, et al.  Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998;21:317–321
  129. Eilber FC, Rosen G, Eckardt J, et al.  Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J. Clin. Oncol. 2001;19:3203–3209
  130. Pratt CB, Maurer HM, Gieser P, et al.  Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: A Pediatric Oncology Group Study. Med Pediatr Oncol. 1998;30:201–209
  131. Demetri GD, Fletcher CD, Mueller E, et al.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA. 1999;96:3951–3956
  132. van Oosterom AT, Judson I, Verweij J, et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421–1423
  133. Verweij J, van Oosterom A, Blay JY, et al.  Imatinib mesylate (STI-571 Glivec(R), Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003;39:2006–2011

PII: S0305-7372(03)00204-4

doi: 10.1016/j.ctrv.2003.11.001

Cancer Treatment Reviews
Volume 30, Issue 3 , Pages 269-280 , May 2004

Article Tools

* Image Usage & Resolution